WASHINGTON, D.C. — In a significant move to address one of the most persistent and frustrating hurdles in modern medicine, the National Organization for Rare Disorders (NORD®) has announced a major partnership with Amgen to launch a specialized Learning Collaborative. Operating through NORD’s esteemed Rare Disease Centers of Excellence Network, the 14-month pilot initiative is specifically designed to slash the time it takes for patients to receive an accurate rare disease diagnosis—a critical gap in care that leaves millions of individuals stranded in diagnostic limbo.
Supported by a targeted sponsorship investment from Amgen, this new collaborative will bring together five to eight participating medical institutions to tackle the entrenched challenges of diagnosing and managing complex rare autoimmune conditions. The initiative will initially focus its efforts on IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both of these conditions are notoriously difficult to recognize in clinical settings, often presenting with vague or overlapping symptoms that require coordinated care across multiple medical specialties, frequently leading to prolonged diagnostic odysseys for patients.
Through the structured framework of the pilot, clinicians from the participating NORD Rare Disease Centers of Excellence will collaborate directly with patients, family caregivers, and disease-specific advocacy organizations. Together, they will closely examine where the current healthcare journey breaks down, mapping out critical friction points in the diagnostic process, specialist referral pathways, treatment decisions, and overall care coordination. By drawing heavily on real-world clinical experience, direct patient insights, and systematic reviews of existing care pathways, the collaborative aims to pinpoint tangible opportunities for improvement and develop practical, actionable resources for clinicians on the front lines of medicine.
The overarching design of the initiative yields a dual benefit, generating two distinct categories of valuable learning. First, it will establish disease-specific approaches aimed at dramatically improving clinical recognition and care pathways specifically for IgG4-RD and TED. Second, it will harvest broader institutional insights into systemic diagnostic delays, specialist referral bottlenecks, and care coordination breakdowns that can be readily applied to a wide array of other rare diseases facing similar structural obstacles. Participating medical centers will regularly share their findings, allowing the network to refine and adapt successful strategies that can ultimately be implemented across diverse healthcare institutions nationwide.
Pam Gavin, President and Chief Executive Officer of NORD, emphasized the collaborative philosophy driving the new network. When NORD originally established its Rare Disease Centers of Excellence network, the core vision was to harness the collective expertise, research power, and clinical resources of the nation’s leading medical institutions to tackle systemic challenges that no single hospital or clinic could possibly solve on its own. Gavin noted that Amgen shares a deep, long-standing commitment to the rare disease community, immediately recognizing the immense potential of the network and stepping forward to help translate that ambitious vision into tangible reality. By working collaboratively across institutional boundaries and side-by-side with patients and clinical experts, Gavin stressed that there is a profound opportunity to solve challenges unique to IgG4-RD and TED while simultaneously forging pathways that will ultimately benefit countless other rare disease communities.
This newly unveiled Learning Collaborative also directly advances the strategic goals of SPAARK, which stands for Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge. SPAARK is an Amgen-led alliance comprising 10 distinct advocacy and professional organizations, including NORD, all united around a shared mission to reduce the time it takes to diagnose rare autoimmune diseases by 50 percent by the year 2036.

The human toll of these diagnostic delays is a central driving force behind the initiative. Kat Provencher, Director of Patient Advocacy at the IgG4ward! Foundation, spoke to the daily realities faced by families navigating these complex health crises. As a caregiver to her husband, Andy, who lives with IgG4-related disease, Provencher understands firsthand how deeply overwhelming it can be to navigate an intricate medical landscape while desperately searching for accurate answers and appropriate care. She pointed out that for families like hers and countless others across the country, the trials and tribulations do not simply vanish once a diagnosis is finally secured. Coordinating ongoing care across a fractured landscape of disparate medical specialists and trying to comprehend the long-term path forward can prove just as arduous. Provencher expressed profound hope for the new collaboration, noting that giving patients and caregivers a direct, influential voice in identifying where the healthcare system falls short will help shape meaningful solutions capable of easing the journey for future families.
Echoing these sentiments, Dr. Paul Burton, senior vice president and chief medical officer at Amgen, highlighted the urgent need for systemic transformation. For far too many individuals living with rare autoimmune diseases, the path leading from initial symptom onset to an accurate diagnosis and appropriate clinical management is far too long and shrouded in unnecessary uncertainty. Dr. Burton emphasized that patients unequivocally deserve answers much sooner in their medical journeys. Through this strategic partnership with NORD and the dedicated members of the SPAARK alliance, Amgen is successfully bringing together diverse perspectives, deep scientific expertise, and institutional grit to systematically dismantle barriers to timely diagnosis, accelerate clinical progress, and ensure that more people gain access to the comprehensive care and vital support systems they require.
Established originally in 2021, NORD’s Rare Disease Centers of Excellence network has grown into a formidable force in American healthcare, currently encompassing 49 designated medical centers that span more than 170 affiliated hospitals, academic medical centers, and research institutions. The network was purposefully built to connect specialized clinical expertise with advanced institutional resources to bridge glaring gaps in rare disease diagnosis and treatment. The newly launched Learning Collaborative directly builds upon that robust foundation by establishing a formal, structured mechanism for these leading institutions to learn dynamically from one another and co-create practical solutions to shared operational and clinical challenges.
To maintain the highest standards of scientific integrity and objectivity, NORD will retain absolute independent scientific oversight of the collaborative initiative throughout its duration. Furthermore, all educational resources and clinical tools developed through the pilot will be carefully crafted to support evidence-based, patient-centered medical care, ensuring they remain entirely free from the promotion of any specific pharmaceutical medication or proprietary treatment approach.
Founded in 1983, the National Organization for Rare Disorders stands as a leading independent, nonpartisan nonprofit organization dedicated entirely to improving the health, wellbeing, and overall quality of life for the more than 30 million Americans currently living with rare diseases. Representing an expansive coalition of more than 350 disease-specific member patient organizations alongside its 49 designated Rare Disease Centers of Excellence and over 170 affiliated institutions, NORD continues to drive vital advancements across the spectrum of patient care, cutting-edge research, public education, and legislative advocacy.
Media inquiries and requests for further information regarding the launch of the Learning Collaborative can be directed to Cheryl Herbert at the National Organization for Rare Disorders.
